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Streszczenie
Formowanie nowych naczyń krwionośnych jest istotnym
czynnikiem w procesie rozwoju nowotworu oraz dawaniu
przerzutów odległych. Dlatego też badania nad czynnika-
mi proangiogennymi oraz antyangiogennymi przyciągają
uwagę wielu badaczy. W niniejszej pracy przedstwiamy
czynniki pro- i antyangiogenne oraz ich rolę w tworzeniu
nowych naczyń krwionośnych w guzach nadnerczy. Oce-
na procesów angiogenezy, jak również ocena wzoru naczy-
niowego w guzach nadnerczy, może być istotna dla roz-
różnienia pomiędzy zmianami złośliwymi a łagodnymi.
Wiedza na temat angiogenezy może być zatem pomocna
w poszukiwaniu nowych strategii leczenia u chorych ze zło-
śliwymi guzami nadnerczy.
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Abstract
It appears that neoangiogenesis is an important factor in
tumour invasion and the formation of metastases in several
human cancers, and studies on pro-angiogenic and anti-
angiogenic factors are therefore of considerable interest to
researchers. In this review we present pro-angiogenic and
anti-angiogenic factors and other growth factors and their
role in the formation of new blood vessels in adrenal tumo-
urs. Assessment of the angiogenic status of adrenal tumours
and their vascular pattern may be useful for discriminating
benign from malignant lesions and knowledge of their an-
giogenesis may be essential to the drawing up of promising
treatment strategies for patients with malignant tumours.
(Pol J Endocrinol 2006; 6 (57): 633–640)
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Introduction
Neoangiogenesis appears to be an important factor in
tumour invasion and the formation of metastases in
several human cancers, and studies on pro-angiogenic
and anti-angiogenic factors are therefore of considera-
ble interest to researchers. In this review pro-angioge-
nic and anti-angiogenic factors and other growth fac-
tors [1] are presented along with their role in the for-
mation of new blood vessels in adrenal tumours.
Pro-angiogenic factors can be classified into several
groups. As shown in Table I, these are heparin-binding
growth factors, mediators of inflammation, hormones
and adhesive molecules.
Vascular endolethial growth factor (VEGF) is one of
the most important pro-angiogenic factors. VEGF is
expressed on the endothelial cells [2–5] and in the stro-
ma [6]. It acts through a VEGF receptor. The signalling
pathway after the binding of VEGF to its receptor inclu-
des dimerisation and activation of thyrosine kinase [7].
So far three VEGF receptors have been investigated.
VEGFR1 is involved in the signalling pathway, VEGFR2
appears to play a role in regulatory processes and
VEGFR3 is connected with the process of lymphangio-
genesis. The regulatory agents of VEGF gene expres-
sion include hypoxia, growth factor cytokines, hormo-
nes [8] and pharmacological agents. In conditions of
hypoxia VEGF gene expression is increased. This ove-
rexpression is mediated via hypoxia-inducible factor-1
(HIF-1). HIF-1 consists of an HIF-1 alpha subunit and
an HIF-1 beta subunit. The former is stable in condi-
tions of hypoxia but unstable in the presence of oxy-
gen. The latter is constitutively expressed. Dimer HIF-1
binds to the hypoxia response element in the VEGF gene
promoter and induces VEGF gene transcription. Expres-
sion of VEGF is also regulated by other factors such as
EGF (epidermal growth factor), TGF beta (transforming
growth factor beta), FGF (fibroblast growth factor), IGF-1
(insulin growth factor-1) and IL-1 (interleukin-1) [9–13].
Within the VEGF gene there are two untranslated re-
gions (near the 3’ end and the 5’ end). Oestrogens are
able to bind to these regions and develop an inhibitory
or stimulatory effect on VEGF gene expression [14].
Other hormones involved in the regulation of VEGF
gene expression are growth hormone and IGF-1. It is
known that growth hormone decreases VEGF gene
expression. Some authors [15] suggest that GH and IGF-1
have an influence on VEGF gene expression via p44/42
MAPK (mitogen activated protein kinase) activation.
There have also been studies which provide evidence
that testosterone may increase VEGF gene expression
[16]. Misztal-Dethloff et al. observed a stimulatory ef-
fect of leptin on the secretion of VEGF from cultured
endothelial cells [17]. Komorowski et al. revealed that
thalidomide decreased secretion of VEGF in endothe-
lial cell cultures [18]. There are also data to suggest that
psychotropic agents (diazepam and chlorpromazine)
can inhibit secretion of VEGF from cultured endothe-
lial cells [19].
Among the anti-angiogenic factors there are natu-
ral fragments of proteins, polypeptide modulators and
hormones (Tab. II) Angiostatin is one of the most po-
Table I
Pro-angiogenic factors
Tabela I
Czynniki proangiogenne
Heparin-binding growth factors Vascular endothelial growth factor (VEGF)
Basic fibroblast growth factor (bFGF)
Platelet-derived endothelial cell growth factor (PDGF)
Hepatocyte growth/scatter factor (HGFSF)
Pleiothropin
Mediators of inflammation Tumour necrosis factor alpha (TNF-alpha)
Interleukins (IL-8, IL-3)
Hormones Oestrogens
Proliferin
Substance P
Erythropoetin
Adhesive molecules Vascular cell adhesion molecule 1 (VCAM-1)
Intracellular adhesion molecule 1 (ICAM-1)
E-selectin
Other growth factors Transforming growth factor beta (TGF-beta)
Epidermal growth factor (EGF)
Insulin-like growth factor
Agiopoetins 1,2,3
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tent anti-angiogenic factors. It is a product of the enzy-
matic cleavage of plasminogen, which binds to the al-
pha subunit of ATP synthase and disturbs ATP synthe-
sis. Angiostatin may therefore render endothelial cells
more sensitive to hypoxic stress [20].
Angiogenesis in normal adrenal glands
and in adrenal tumours
Normal adrenal glands are highly vascularised endo-
crine glands located in the retroperitoneal space just
above or alongside the superior poles of the kidneys.
They are supplied with blood by the phrenic artery,
renal artery, and aorta. Thanks to the fenestrated epi-
thelium lining their vessels they are permeable to the
hormone produced in these glands [21, 22]. This per-
meability of the epithelium enables hormones and cy-
tokines to be transported from the cells surrounding
the vessels and from the blood to the perivascular envi-
ronment. During foetal life vascularisation of the adre-
nal glands is first observed at the eighth week of pre-
gnancy [23]. Shifren et al. examined the foetal adrenal
glands at mid-gestation, between the 16th and 20th we-
eks of pregnancy and assessed the expression of VEGF
mRNA. They revealed that immunocytochemical sta-
ining for VEGF mRNA was most abundant in the foetal
zone of the foetal adrenal gland. Moreover, VEGF
expression and secretion by the foetal adrenal cortical
cells was up-regulated by ACTH. High expression of
VEGF mRNA was associated with rich vascularisation
of the foetal adrenal glands, as confirmed by positive
immunocytochemical staining for the von Willebrand
factor A marker of endothelial cells [24]. Bernini et al. [25]
examined the expression of cytoplasmatic VEGF using
antibodies anti-VEGF in human normal adrenal glands,
aldosterone-producing adenomas (APA), cortisol-pro-
ducing adenomas (CPA), non-functioning cortical ade-
nomas (NFA) and adrenal cortical carcinomas (ACC).
The highest expression of cytoplasmatic VEGF was exhi-
bited by cells of ACC and the lowest by those of NFA.
Expression of VEGF in APA was higher than in normal
cortex cells, while in CPA it was comparable to expres-
sion in normal cells. It is interesting that in patients with
adrenal tumours (benign or malignant) serum VEGF is
also increased. After surgical resection serum VEGF was
decreased (measured one month after operation) [26].
The measurement of circulating plasma levels of
VEGF and its soluble receptors, sVEGFR-1 and sVEGFR-2
(acting as an inhibitor for VEGF), in patients with adre-
nal tumours appears to be of use in the prediction of
tumour malignancy. Korzeniewska et al. [27] revealed
that patients with adrenocortical carcinoma had the
highest VEGF and the lowest sVEGFR-2 serum concen-
trations when compared to the control group. Patients
with adrenocortical adenomas had VEGF serum con-
centrations comparable to the control group, but
sVEGFR-1 and sVEGFR-2 were lower than in the con-
trol group. Of patients with metastases to the adrenal
glands VEGF concentration was higher than in controls
but not as high as in patients with adrenocortical carci-
noma. Increased serum concentrations of VEGF were
also observed in other endocrine tumours such as thy-
roid [28] and pituitary tumours [29].
 Fraipont et al. [30] measured the cytosolic concen-
trations of three proteins (VEGF, trombospondin and
platelet-derived endothelial growth factor) involved in
angiogenesis in adrenal tumours and assessed the cor-
relation between the concentration of these proteins and
genetic alterations occurring in adrenocortical tumours.
From an examination of 18 adenomas, 12 transitional
tumours and 13 carcinomas they revealed that platelet-
derived endothelial cell growth factor (thymidine pho-
sphorylase) cytosolic concentration did not differ be-
tween these groups. VEGF concentration was increased
in the carcinomas, but, in contrast, in adenomas and
transitional tumours concentrations of VEGF were not
elevated. Expression of trombospondin 1(TSP1), an anti-
angiogenic factor measured in this study, was decre-
ased in carcinomas and transitional tumours as compa-
red to adenomas. The authors of this research suggest
that a low concentration of TSP1 is the first event in the
multi-step process of evolution from benign to mali-
gnant lesions. Allelic loss at the 11p15 accompanied by
overexpression of IGF-II is the most frequent genetic
disturbance observed in adrenocortical tumours. In this
study a correlation was observed between overexpres-
sion of IGF-II and a higher concentration of cytosolic
Table II
Anti-angiogenic factors
Tabela II
Czynniki antyangiogenne
Natural fragments of proteins Angiostatin
and polypeptide modulators Endostatin
AaAT (fragment of
antithrombin 3)
Prolactin (16 kDa fragment)
Trombospondin 1
Troponin I
Interferons (IFN-a, IFN-b)
Platelet factors-4
Interleukins (IL-12, IL-4)
Tissue inhibitors of matrix
metalloproteinase (TIMP-1,
TIMP-2)
Hormones Testosterone
Methoxyestradiol
Somatostatin
Melatonin
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VEGF and a lower concentration of TSP-1. This genetic
disturbance occurs most frequently in localised malig-
nant adrenocortical tumours and transitional tumours
but is not common in benign lesions [31]. The authors
also suggest that a high cytosolic concentration of VEGF
may be a marker of tumour recurrence, but in this stu-
dy the group examined was too small to establish the
predictive value of this finding.
Zacharieva et al. [32] assessed circulating levels of
VEGF, active renin and urinary prostaglandin E2 (PGE2)
excretion in patients with adrenal tumours. The highest
plasma levels of VEGF were found in adrenocortical
carcinomas (statistically significant when compared
to VEGF level in patients with pheochromocytoma and
primary hyperaldosteronism). VEGF levels were also
elevated in patients witch Cushing’s syndrome, prima-
ry hyperaldosteronism and pheochromocytoma. The
former group of patients had higher plasma VEGF le-
vels than cases with pheochromocytoma and primary
hyperaldosteronism. Plasma active rennin levels were
highest in patients with pheochromocytoma and lowest
in patients with primary hyperaldosteronism as com-
pared to control, patients with Cushing’s syndrome and
patients with adrenocortical carcinoma. Urinary excre-
tion of PGE2 did not differ between these groups. The
authors of this work suggest that the angiogenic status
of adrenal tumours is associated with tumour malignan-
cy and is also related to the hormonal activity of the
tumour. VEGF has a mitogenic effect on endothelial cells
and also induces expression of matrix metalloproteina-
ses (MMPs), which are involved in angiogenesis [33].
MMPs are zinc-dependent endopeptidases that are able
to dissolve extracellular matrix. It is known that MMP-2
and MMP-9 play the most important roles in the pro-
cess of degradation of the major component of the extra-
cellular matrix, namely type IV collagen [34]. The acti-
vity of MMPs is regulated by their tissue inhibitors
(TIMPs, tissue inhibitors of MMPs). TIMPs bind active
MMPs with a 1:1 stoichiometry and it is due to this bin-
ding that MMPs do not exhibit endopeptidase activity [35].
There have been studies suggesting that growth fac-
tors and cytokines are involved in regulation of the
expression of MMPs. Randeva et al. revealed that
growth hormone decreased serum levels of MMP-2 and
MMP-9 in adults deficient in growth hormone [36]. Ac-
tivation of some MMPs requires the presence of plas-
min, a peptide that is formed during enzymatic cle-
avage of plasminogen [37]. Increased levels of some
MMPs and an imbalance between MMPs and their in-
hibitors (TIMPs) are described in several human can-
cers. Maruayma et al. revealed increased serum con-
centrations of MMP-2 and MMP-9 and undetectable
concentrations of TIMP-2 in patients with papillary thy-
roid carcinoma [38]. Extensive studies by Komorowski
et al. showed [39] elevated serum levels of MMP-2 and
slightly elevated serum levels of TIMP-2 in patients with
all histological types of thyroid cancer. Additionally,
increased levels of MMP-3 and MMP-9 were observed
in patients with medullary thyroid cancer. It is repor-
ted that MMPs are also involved in angiogenesis in ad-
renal tumours by degradation of the extracellular ma-
trix. MMP-2 is present in the cells of malignant cortical
tumours but not in stroma [40]. Kjellman et al. [40] exa-
mined 30 adrenal tumours for gelatinase A, membrane
type 1 matrix metalloproteinase (MT 1-MMP) and col-
lagenase-3. The tests revealed that gelatinase A mRNA
was expressed in stromal cells in most malignant tumours
(13 out of 16 carcinomas) but not in benign lesions (only 1
out of 14). Kołomecki et al. [41] compared serum levels
of MMP-3 between patients with adrenocortical carci-
noma and benign adrenal tumours (hormonally inacti-
ve), revealing that the former group of patients had si-
gnificantly higher levels of MMP-3 than patients with
benign lesions. They also assessed serum levels of MMP-3
after surgical treatment of adrenal tumours and obser-
ved a normalisation of these. Serum MMP-3 levels in-
creased again only in patients with recurrence.
There are also data to confirm the anti-angiogenic
properties of MMP-9 (one of the enzymes that convert
plasminogen to angiostatin) [42]. Grosset et al. [43] exa-
mined pheochromocytoma in von Hippel-Lindau di-
sease (VHL). VHL is a cancer syndrome inherited in an
autosomal dominant manner. The most common alte-
rations occurring in VHL syndrome are renal cell carci-
noma, retinal angiomas and cerebellar and spinal cord
haemangioblastomas. It is interesting that patients with
VHL syndrome exhibited high expression of VEGF
mRNA. This is due to the unresponsiveness of VEGF to
normoxia/hypoxia regulation, the effect of mutation in
VHL, which is one of the suppressor genes. In this stu-
dy expression of MMPs and collagen 1 (the major com-
ponents of the extracellular matrix [44, 45]) was asses-
sed in pheochromocytoma derived from patients with
VHL syndrome. After surgical treatment fragments of
tumour were transplanted s.c. to nude mice and treat-
ment with halofunginone (an anti-tumoral agent which
exhibits anti-angiogenic properties) was performed.
Levels of collagen 1 and vascular density were assessed
in the tumour before and after halofunginone treatment
with the use of immunohistochemical assays. This stu-
dy revealed decreased levels of collagen type 1 and
decreased expression of MMP-2 and MMP-9 after halo-
funginone treatment. Additionally, tumour size was
diminished after halofunginone treatment. Another
pro-angiogenic factor is bFGF, which is presumably in-
volved in angiogenesis in pheochromocytoma and che-
modetectoma [46]. Statuto et al. examined normal ad-
renal medulla, pheochromocytoma and chemodetectoma.
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This study showed that levels of immunoreactive
and biologically active bFGF were elevated in pheochro-
mocytoma and chemodetectoma as compared to nor-
mal adrenal medulla. Pheochromocytoma exhibited im-
munostaining for bFGF in the nuclei of the chief cells
and the endothelial cells (likewise normal adrenal medul-
la). Cytoplasmatic bFGF in endothelial cells was detected
in the pheochromocytoma but not in the normal gland.
Investigation of SW-13 human adrenocortical carci-
noma cells [47, 48] revealed that endothelins might be
involved in angiogenesis and tumour cell growth.
SW-13 exhibits a low ability to synthesise steroid hor-
mones owing to a lack of the organelles which are
involved in this process. Because of the expression of
two vasoactive peptides, proendothelin-1 (pro ET-1) and
adrenomedullin (AM) and their receptors, SW-13 is
a good model for investigating autocrine/paracrine con-
trol of the growth of adrenocortical carcinoma. Taka-
hashi et al. [49] examined the influence of cytokines such
as TNF alpha (tumour necrosis factor alpha), IFN-gam-
ma (interferon gamma) and IL-1 on the secretion of AM
and endothelin-1 by SW-13 human adrenocortical car-
cinoma cells. They revealed that TNF-alpha stimulated
synthesis of both vasoactive peptides. IFN-gamma in-
duces synthesis of endothelin-1 but not AM, while IL-1
increases the synthesis of adrenomedullin but has no
effect on the synthesis of endothelin-1.
Donckier et al. [50] described patients with Cushing’s
syndrome in the course of adrenocortical carcinoma.
Immunohistochemical analysis of the excised tumour
revealed a high expression of endothelin-1. Endothe-
lins may also be involved in the process of angiogene-
sis in pheochromocytomas.
Favier et al. [51] revealed overexpression of endo-
thelin receptor ETB in endothelial cells and endothelin
receptor ETA in pericytes or tumour cells in malignant
tumours. They suggest that this overexpression and the
vascular pattern of tumours are the most important fac-
tors in distinguishing benign from malignant lesions.
The precursors of endothelins, PPET-1 and PPET-3,
were not overexpressed in malignant tumours. The
authors of this research suggest that migration and pro-
liferation of endothelial cells is stimulated by ET-3 ac-
ting via ETB receptors. They also investigated the strong
positive correlation between expression of VEGF and
EPAS-1 (transcriptive factor), but no correlation was
observed between expression of VEGF and HIF 1 al-
pha. The authors of this study also suggest that the an-
giopoetin system does not take part in angiogenesis in
pheochromocytomas.
 Some authors suggest that prokineticins (endocri-
ne gland vascular endothelial factors) may take part in
angiogenesis [52]. Chi-Hong Lin et al. [53] described two
receptors for prokineticins, PKR1 and PKR2, and their
tissue distribution. These receptors are expressed in
many endocrine (adrenal gland, thyroid gland, pituita-
ry gland, testis and ovary) and non-endocrine (small
intestine, colon and rectum) tissues and are G-protein-
coupled receptors. Activation of these receptors via pro-
kineticins leads to phosphorylation of p44/42MAPK,
which is crucial for angiogenesis [54].
Some studies [55] provide evidence that the loss of
cell adhesion may result in cell invasiveness. There is a
family of proteins (the CCN family) that include ctg f
[56], cyr 61[57] and nov H. Proteins that belong to this
family possess adhesive, angiogenic, mitogenic and
chemotactic properties. Of the endocrine tissues the
adrenal glands are the major site of nov H expression,
both foetal and adult adrenal glands being involved
(nov H is predominantly expressed in the adrenal cor-
tex.) It is likely that nov H is associated with cell adhe-
sion and participates in a signalling pathway involving
the extracellular matrix. Martinerie et al. [55] examined
expression of nov H mRNA in 12 benign and 18 mali-
gnant adrenocortical tumours. They revealed that
expression of nov H is significantly lower in a malignant
tumour than in a benign lesion, suggesting that cell in-
vasiveness is related to loss of cell adhesion as a result
of a low level of expression of nov H. They also reve-
aled that benign lesions possessed another N-glycosy-
lation profile of nov H when compared to malignant
lesions, but the site of expression of nov H did not dif-
fer between benign and malignant tumours.
It has been reported that an increased level of solu-
ble forms of immunoglobulin-like adhesive molecules
(sICAM-1, sVCAM-1) is related to a malignant course
of many endocrine tumours. ICAM-1 and VCAM-1 are
expressed on the surface of the lymphocytes and are
able to bind to the corresponding molecules (such as
integrins) on the neoplastic cells. They are, therefore,
involved in the process of intercellular adhesion. Their
soluble forms can bind to the corresponding molecules
and decrease adhesion between cells and also allow
neoplastic cells to avoid immunological response. The-
se alterations have been observed in several human can-
cers such as thyroid cancer [58], lung cancer [59], ova-
rian cancer [60] and breast cancer [61]. There are also
unpublished data (Stępień et al.) to indicate that in pa-
tients with adrenal cortex carcinoma levels of sICAM-1
and sVCAM-1 are significantly increased.
Fraipont et al. [62], using cDNA microarrays, descri-
bed the gene profile related to the malignant course of
adrenal tumours. They identified two clusters of genes,
termed the IGF II-cluster and the steroidogenesis clu-
ster. It is interesting that in the IGF-II cluster there are
the FGFR1 and FGFR4 genes (chromosome location
8p11.2-p11.1 and 5q35.1-qter respectively), which en-
code thyrosine kinase receptors type 1 and 4. FGF1 and
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FGF 2 expressed in the adrenal cortex act via these re-
ceptors and may develop a mitogenic effect on endo-
thelial, mesenchymal and steroidogenic adrenocortical
cells [63]. In this report the authors suggest that overe-
xpression of FGFR1 and 4 in adrenocortical carcinomas
may be linked to increased proliferation and vasculari-
sation of these tumours. The TGF beta gene and the
gene encoding its type 1 receptor (TGF beta R1) also
cosegregate with the IGF-II cluster. TGF beta 2 (resem-
bling TGF beta 1) is known to have an inhibitory effect
on adrenocortical steroidogenesis. The authors of this
work suggest that overexpression of TGF beta-2 and
TGF beta R-1 in adrenocortical carcinomas may interfere
with the differentiation of these tumours. The IGF-II
cluster also includes the MST1R gene, encoding a thy-
rosine kinase receptor for macrophage-stimulating pro-
tein 1, a potent mitogen for the adrenomedullary cells.
The IGF-II cluster also includes the KCNQ10T1 gene
and the IGF-II gene, located in the same region of the
11p15.5. The product of KCNQ10T1 is a non-coding
anti-sense transcript, which is presumably involved in
regulatory processes linked with the paternal imprin-
ting of the centromere domain of the 11p15 region. The
high expression of IGF-II in malignant tumours is due
to loss of the maternal allele and duplication of the pa-
ternal allele (paternal isodisomy) [64, 65]
Ciquel et al. [64] examined mutations at the 11p15
locus in sporadic adrenocortical tumours (6 carcinomas
and 17 adenomas) and revealed that mutations at this
locus are frequent in malignant tumours but rare in
benign lesions. The most frequent disturbance occur-
ring at 11p15 was uniparental disomy. Tumours with
uniparental disomy also exhibited a high serum IGF-II
concentration.
Research into adrenal tumours in genetic syndro-
mes [65] (Beckwith-Wiedemann, Li-Fraumeni, McCu-
ne-Albright, Carney) and multiple endocrine neoplasia
type I has demonstrated that mutations at the 11p15
locus have been associated with overexpression of
growth promotion factors. It is reported that some mu-
tations in mitochondrial genes are related to the angio-
genesis and malignant course of pheochromocytoma [66].
Mitochondrial complex II is involved in the Krebs cycle
and aerobic electron transport chain. It contains four
subunits: subunit A (flavoprotein) and subunit B (iron-
sulphur) protein, which possess catalytic properties,
while subunits C and D are an anchorage domain.
Mutations in the SDHD and SDHB gene in mitochon-
drial complex II result in a loss of activity of the com-
plex and activation of the hypoxic/angiogenic pathway.
The markers of this activation are endothelial PAS do-
main protein 1 (EPAS -1), hypoxia inducible factor 1 al-
pha (HIF-1alpha) and VEGF) [67]. The authors descri-
bed a germline mutation at the R46Q position of the
SDHD gene related to a malignant course of pheochro-
mocytoma. Astuti et al. [68] described a frameshift mu-
tation within exon six of the SDHB gene linked with
a benign course of pheochromocytoma. Assessment of
vascular pattern in pheochromocytomas may be a use-
ful tool in distinguishing benign from malignant lesions.
Favier et al. [51] examined 19 pcheochromocytomas (ten
benign, nine malignant). This study showed evidence
that all malignant pheochromocytomas presented an
abnormal vessel pattern of irregular blood vessels, flat-
tened between tumour nodules, with larger diameters
than normal blood vessels. Sasano et al. [69] reported
that the vascular density of adrenocortical carcinoma
measured as the number of vessels per mm2 did not
differ from the vascular density of adrenocortical ade-
nomas and the normal cortex, suggesting that adreno-
cortical carcinomas are not highly vascularised tumo-
urs but that they have an increased angiogenic poten-
tial expressed by the greater endothelial area of each
vessel (EA, microm2/vessel) and a greater vascular area
(the percentage of EA per field).
In summary, assessment of the angiogenic status of
adrenal tumours and their vascular pattern may be use-
ful for discriminating benign from malignant lesions and
knowledge of angiogenesis may be essential in drawing
up promising treatment strategies in patients with ma-
lignant tumours.
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